AVDR - Avedro, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.01
-0.31 (-2.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.32
Open12.31
Bid0.00 x 800
Ask0.00 x 800
Day's Range12.01 - 12.50
52 Week Range10.75 - 14.20
Volume30,847
Avg. Volume187,742
Market Cap204.948M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-17.97
Earnings DateMay 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.75
Trade prices are not sourced from all markets
  • GlobeNewswire16 hours ago

    Avedro, Inc. to Report First Quarter 2019 Financial Results on May 9, 2019

    WALTHAM, Mass., April 25, 2019 -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”) today announced that it will release financial results for the first quarter of 2019 after the close of.

  • GlobeNewswire4 days ago

    Avedro to Present Research on Proprietary Corneal Cross-Linking Technologies at 2019 ARVO Annual Meeting

    WALTHAM, Mass., April 22, 2019 -- Avedro, Inc. (Nasdaq: AVDR) (Avedro), today announced that three abstracts highlighting proprietary cross-linking technologies being developed.

  • GlobeNewswire21 days ago

    Avedro Reaches Reimbursement Milestone for Its FDA-Approved Procedure for Progressive Keratoconus

    Avedro, Inc., (Avedro or the company), today announced that four new providers --Providence Health Plan in the Pacific Northwest, Health New England, HealthPartners Minnesota and Public Employees Health Plan (PEHP) in Utah--have issued positive coverage policies for Avedro’s FDA-approved corneal cross-linking procedure, bringing the total number of commercial plans covering the KXL system and its associated Photrexa® drug formulations to over 65.

  • GlobeNewswirelast month

    Avedro, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Financial Outlook

    WALTHAM, Mass., March 21, 2019 -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic.

  • ACCESSWIRElast month

    Avedro, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Avedro, Inc. (NASDAQ: AVDR ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 21, 2019 at 4:30 PM Eastern ...

  • GlobeNewswirelast month

    Avedro, Inc. Announces Appointment of Patrick B. Jacques as Vice President of Sales

    Avedro, Inc. (AVDR) (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today announced the appointment of Patrick B. Jacques as Vice President of Sales, effective immediately. Reporting to James Schuermann, Avedro’s Chief Business Officer, Mr. Jacques will be responsible for directing Avedro’s U.S. sales strategy, building relationships with clinicians and other key partners, and contributing to Avedro’s marketing programs.

  • GlobeNewswire2 months ago

    Avedro, Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on March 21, 2019

    WALTHAM, Mass., Feb. 28, 2019 -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic.

  • GlobeNewswire2 months ago

    Avedro Announces Pricing of Initial Public Offering

    Avedro, Inc. (AVDR) (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $14.00 per share, for total gross proceeds of $70.0 million. BofA Merrill Lynch and J.P. Morgan are acting as joint book-running managers for the offering. Cowen, Guggenheim Securities and SVB Leerink are acting as co-managers for the offering.

  • Benzinga2 months ago

    IPO Outlook For The Week: Biotechs And Another Virgin Group Addition

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Anchiano Therapeutics Ltd. (ANCN) will issue 2.4 million shares at $14.55 ...